May 1 (Reuters) - Post position for Saturday's 139th Kentucky Derby at Churchill Downs after Wednesday's draw (listed as barrier, HORSE, jockey, trainer) 1. BLACK ONYX, Joe Bravo, Kelly Breen 2. OXBOW, Gary Stevens, D. Wayne Lukas 3. REVOLUTIONARY, Calvin Borel, Todd Pletcher 4. GOLDEN SOUL, Robby Albarado, Dallas Stewart 5. NORMANDY INVASION, Javier Castellano, Chad Brown 6. MYLUTE, Rosie Napravnik, Tom Amoss 7. GIANT FINISH, Jose Espinoza, Tony Dutrow 8. GOLDENCENTS, Kevin Krigger, Doug O'Neill 9. OVERANALYZE, Rafael Bejarano, Todd Pletcher 10. PALACE MALICE, Mike Smith, Todd Pletcher 11. ...
But this year's May Day demonstrations come on the heels of the tragic Bangladesh factory collapse, a potent symbol for many of the importance of workers' rights.
By Ryan Lenora Brown,?Correspondent / May 1, 2013
Workers and protesters hold a huge banner march to the government office during a May Day rally in Hong Kong, Wednesday. Hundreds of workers, local labor right groups, and striking dockworkers join the annual rally to demand better wages and working conditions.
Vincent Yu/AP
Enlarge
In Dhaka, Bangladesh, a raucous crowd descended on the city center with signs and drums, chanting and waving banners demanding the death penalty for the owner of a factory where more than 400 people died in a building collapse last week.
Skip to next paragraph Ryan Lenora Brown
Correspondent
Ryan Brown edits the Africa Monitor blog and contributes to the national and international news desks of the Monitor. She is a former Fulbright fellow to South Africa and holds a degree in history from Duke University.?
Click Here for your FREE 30 DAYS of The Christian Science Monitor Weekly Digital Edition
In Jakarta, Indonesia, some of the tens of thousands of demonstrators marching through the city came dressed as ants ? complete with bright red outfits and antennae ? to depict the exploitation of workers.?
And in Greece, trains, buses, and ferries sat vacant and hospitals nearly empty as thousands of public sector employees walked off the job in a one-day strike.
Each year, May 1, better known as May Day, is marked with labor rallies and strikes around the world. And this year's holiday came at a particularly prescient moment in many parts of the world.?
From Europe, where the bite of austerity has left many facing down unemployment and reduced benefits, to South and Southeast Asia, a region cluttered with precariously-built factories similar to the one that collapsed last week in Bangladesh, demonstrators gathered to vent outrage and demand reform.
?My brother has died. My sister has died. Their blood will not be valueless,? yelled one Bangladeshi protestor through a crackling loudspeaker, according to the Associated Press.
As the march wove through downtown Dhaka, rescue workers in the industrial suburb of Savar continued their search for bodies and survivors in the rubble of Rana Plaza, which collapsed suddenly on April 24 with thousands of garment workers inside.
The disaster at the factory, which manufactured clothing for several low-end Western retailers, touched off global outrage about the working conditions of garment workers across the developing world. In Phnom Pehn, Cambodia, workers rallied for higher wages and safer working conditions. In Manila, Philipines, where labor unions are banned, workers marched to demand the right to organize. And in Hong Kong, thousands turned out in support of striking dock workers, calling for wages that would help close the income gap between the country?s rich and its poor.
And that was all before Europe woke up.
There has "never been a May 1 with more reason to take to the streets,? one Spanish union leader told Reuters during a march in Madrid this morning, where protestors carried signs reading "austerity ruins and kills" and "reforms are robbery.? (Read the Monitor's feature about how Spaniards are increasingly flocking to the countryside to cut costs and find new jobs.)
In Greece, where the government recently announced that it would lay off 180,000 civil servants over the next two years ? the first such cuts in 100 years ? a strike shut down public transit across Athens. ?
And in France, which saw unemployment rose again last month, marchers carried banners reading, ?It?s too much! Alternatives exist? and ?Where are the real socialists in our government??
An exception to the doom and gloom of this year?s May Day was Russia, where a festive celebration of the holiday harks back to Soviet times. Indeed, many of those who gathered in the streets of Moscow were buoyant, Euronews reported.
?The atmosphere is excellent. It?s a holiday for us, the beginning of something new, bright, and joyful,? one demonstrator told reporters.
May 1 is a national holiday in some 80 countries around the world, and its ties to labor advocacy date back to 1886, when American police killed 10 protestors at a rally for an eight-hour workday in Chicago?s Haymarket Square. International socialist organization and labor unions declared it a day of commemoration and action soon after.
Ironically, however, May Day is not celebrated in the United States. In the early 1890s, fearing the ?socialist? overtones of the holiday, President Grover Cleveland quickly declared an alternate holiday, beginning the American tradition of celebrating Labor Day on the first Monday of September.?
Large genomic study identifies endometrial cancer subtypes, treatment opportunitiesPublic release date: 1-May-2013 [ | E-mail | Share ]
Contact: Caitlin Hool hoolc@mskcc.org 212-639-3573 Memorial Sloan-Kettering Cancer Center
NEW YORK, MAY 1, 2013 Endometrial tumors can be reclassified into distinct subtypes based partly on their genomic makeup and may respond to targeted drugs already being tested in clinical trials, according to a large-scale genomic analysis led by researchers at Memorial Sloan-Kettering Cancer Center and other centers within The Cancer Genome Atlas (TCGA) Research Network.
Published in the May 2 issue of the journal Nature, the findings may help doctors more accurately diagnose endometrial cancer and choose treatments that will target genomic mutations in women with endometrioid and uterine serous adenocarcinomas, the two most common types of endometrial cancer. The findings could also guide clinical trials and the development of new drugs.
"These findings have an immediate therapeutic application, as patients with endometrial cancer can be tested routinely to see whether they qualify for a targeted therapy clinical trial," said Memorial Sloan-Kettering gynecologic oncologist Douglas A. Levine, MD, corresponding author on the study, principal investigator of Memorial Sloan-Kettering's TCGA Tissue Source Site, and Co-Chair of TCGA's Endometrial Working Group. "The current landscape of treatment for endometrial cancer is quite chaotic, and this research may provide order to that landscape, especially for more-aggressive endometrial cancers."
Endometrial cancer, which forms in the tissues lining the uterus, is the fourth leading type of cancer among women and the eighth leading cause of cancer death. Endometrioid tumors are usually less aggressive, while uterine serous tumors are more aggressive.
There has been little agreement among doctors over the best treatment approach following surgery for patients with a high risk of recurrence, with decisions relying largely on a tumor's pathology. However, it is difficult for pathologists to reliably differentiate high-grade endometrioid tumors from uterine serous tumors.
According to Dr. Levine, incorporating new genomic information into treatment planning could be a great leap forward, helping to make certain that additional therapies are used effectively and only when necessary.
The analysis of 373 endometrial tumors showed that approximately a quarter of high-grade endometrioid tumors have certain types of genomic alterations also found in uterine serous tumors. This suggests that a significant portion of endometrioid tumors should be treated more aggressively after surgery.
Many of the tumors analyzed had mutations in important cancer-related genes and pathways for which targeted therapies are already being tested in clinical trials for other cancers. For example, 84 percent of the tumors have some alteration in the PI3 kinase pathway, which is implicated in many cancers. Additionally, genomic alterations in uterine serous tumors share many features with ovarian serous and triple-negative breast cancers, suggesting opportunity for shared treatments.
Investigators at Memorial Sloan-Kettering are now translating these findings into clinically useful tests that may be applied to ongoing and planned clinical trials.
A project jointly funded by the National Cancer Institute and the National Human Genome Research Institute, TCGA is one of the most comprehensive national efforts to collect and analyze the largest set of tumor samples to date using state-of-the-art genomic and molecular techniques. Memorial Sloan-Kettering currently houses one of TCGA's Genome Data Analysis Centers, led by computational biologist Chris Sander, PhD, biocomputing manager Nikolaus Schultz, PhD, and molecular pathologist Marc Ladanyi, MD. For the endometrial cancer study, Memorial Sloan-Kettering contributed more than 10 percent of all tissue samples analyzed.
###
This research was supported by the National Cancer Institute of the National Institutes of Health (NIH) under awards 5U24CA143799-04, 5U24CA143835-04, 5U24CA143840-04, 5U24CA143843-04, 5U24CA143845-04, 5U24CA143848-04, 5U24CA143858-04, 5U24CA143866-04, 5U24CA143867-04, 5U24CA143882-04, 5U24CA143883-04, 5U24CA144025-04, U54HG003067-11, U54HG003079-10, and U54HG003273-10, and supplemented by the Recovery Act.
Memorial Sloan-Kettering Cancer Center is the world's oldest and largest private institution devoted to prevention, patient care, research, and education in cancer. Our scientists and clinicians generate innovative approaches to better understand, diagnose, and treat cancer. Memorial Sloan-Kettering specialists are leaders in biomedical research and in translating the latest research to advance the standard of cancer care worldwide. For more information, go to http://www.mskcc.org.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Large genomic study identifies endometrial cancer subtypes, treatment opportunitiesPublic release date: 1-May-2013 [ | E-mail | Share ]
Contact: Caitlin Hool hoolc@mskcc.org 212-639-3573 Memorial Sloan-Kettering Cancer Center
NEW YORK, MAY 1, 2013 Endometrial tumors can be reclassified into distinct subtypes based partly on their genomic makeup and may respond to targeted drugs already being tested in clinical trials, according to a large-scale genomic analysis led by researchers at Memorial Sloan-Kettering Cancer Center and other centers within The Cancer Genome Atlas (TCGA) Research Network.
Published in the May 2 issue of the journal Nature, the findings may help doctors more accurately diagnose endometrial cancer and choose treatments that will target genomic mutations in women with endometrioid and uterine serous adenocarcinomas, the two most common types of endometrial cancer. The findings could also guide clinical trials and the development of new drugs.
"These findings have an immediate therapeutic application, as patients with endometrial cancer can be tested routinely to see whether they qualify for a targeted therapy clinical trial," said Memorial Sloan-Kettering gynecologic oncologist Douglas A. Levine, MD, corresponding author on the study, principal investigator of Memorial Sloan-Kettering's TCGA Tissue Source Site, and Co-Chair of TCGA's Endometrial Working Group. "The current landscape of treatment for endometrial cancer is quite chaotic, and this research may provide order to that landscape, especially for more-aggressive endometrial cancers."
Endometrial cancer, which forms in the tissues lining the uterus, is the fourth leading type of cancer among women and the eighth leading cause of cancer death. Endometrioid tumors are usually less aggressive, while uterine serous tumors are more aggressive.
There has been little agreement among doctors over the best treatment approach following surgery for patients with a high risk of recurrence, with decisions relying largely on a tumor's pathology. However, it is difficult for pathologists to reliably differentiate high-grade endometrioid tumors from uterine serous tumors.
According to Dr. Levine, incorporating new genomic information into treatment planning could be a great leap forward, helping to make certain that additional therapies are used effectively and only when necessary.
The analysis of 373 endometrial tumors showed that approximately a quarter of high-grade endometrioid tumors have certain types of genomic alterations also found in uterine serous tumors. This suggests that a significant portion of endometrioid tumors should be treated more aggressively after surgery.
Many of the tumors analyzed had mutations in important cancer-related genes and pathways for which targeted therapies are already being tested in clinical trials for other cancers. For example, 84 percent of the tumors have some alteration in the PI3 kinase pathway, which is implicated in many cancers. Additionally, genomic alterations in uterine serous tumors share many features with ovarian serous and triple-negative breast cancers, suggesting opportunity for shared treatments.
Investigators at Memorial Sloan-Kettering are now translating these findings into clinically useful tests that may be applied to ongoing and planned clinical trials.
A project jointly funded by the National Cancer Institute and the National Human Genome Research Institute, TCGA is one of the most comprehensive national efforts to collect and analyze the largest set of tumor samples to date using state-of-the-art genomic and molecular techniques. Memorial Sloan-Kettering currently houses one of TCGA's Genome Data Analysis Centers, led by computational biologist Chris Sander, PhD, biocomputing manager Nikolaus Schultz, PhD, and molecular pathologist Marc Ladanyi, MD. For the endometrial cancer study, Memorial Sloan-Kettering contributed more than 10 percent of all tissue samples analyzed.
###
This research was supported by the National Cancer Institute of the National Institutes of Health (NIH) under awards 5U24CA143799-04, 5U24CA143835-04, 5U24CA143840-04, 5U24CA143843-04, 5U24CA143845-04, 5U24CA143848-04, 5U24CA143858-04, 5U24CA143866-04, 5U24CA143867-04, 5U24CA143882-04, 5U24CA143883-04, 5U24CA144025-04, U54HG003067-11, U54HG003079-10, and U54HG003273-10, and supplemented by the Recovery Act.
Memorial Sloan-Kettering Cancer Center is the world's oldest and largest private institution devoted to prevention, patient care, research, and education in cancer. Our scientists and clinicians generate innovative approaches to better understand, diagnose, and treat cancer. Memorial Sloan-Kettering specialists are leaders in biomedical research and in translating the latest research to advance the standard of cancer care worldwide. For more information, go to http://www.mskcc.org.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
satellite internet has come a long way. Hughes Net and Exede are the two companies and i recommend Exede. Both offer service around 12 MB/Second and they have data caps.
the basic package is 10GB per month which isnt bad as long as your an average user. if you're streaming Netflix every night you can always do a higher package. A side note= if you have directv or dish network you can bundle and save $10 a month off your bill.
let me know if youre interested, i work in that industry and can have someone set you up. its a great service
The newest episode of 'Game of Thrones' featured many characters, including Emilia Clarke's Daenerys, making some surprising choices.
By Kevin Yeoman,?Screen Rant / April 22, 2013
'Game of Thrones' stars Emilia Clarke.
Mario Anzuoni/Reuters
Enlarge
Revenge may be a dish best served cold, but when it comes to Lord Varys, it?s best served basting in its own retched filth inside a shipping crate that takes about as much effort to open as today?s infernal clamshell packaging.
Skip to next paragraph Screen Rant
Screen Rant had a humble start back in 2003 as a place to rant about some of the dumber stuff related to the movie industry. Since then, the site has grown to cover more and more TV and movie news (and not just the dumb stuff) along with sometimes controversial movie reviews. The goal at Screen Rant is to cover stories and review movies from a middle ground/average person perspective.
Click Here for your FREE 30 DAYS of The Christian Science Monitor Weekly Digital Edition
But like the digressive storylines and carefully plotted machinations of Game of Thrones, a significant portion of Varys? pleasure stems from the patience, scheming and countless other dealings required to see his design come to fruition. There?s been a great deal of maneuvering early on in season 3, but now it seems ready for some kind of pay off. And in a series where there are precious few payoffs each season (?Blackwater? potentially being the biggest of the series so far), the patience of the audience is a must, so even a hint of larger developments can justify an initially slow pace.?
?And Now His Watch Is Ended? is still mostly about maneuverings ? Tyrion wants information on his sister?s alleged involvement in the attempt on his life, so he goes to the one man who apparently knows everything and understands what it is to live as an outcast with a taste for revenge ? but they feel like maneuverings that will amount to something far more personal than who is winning what unseen battle between the Lannisters and the King of the North. Frankly, Tyrion could not have chosen a better moment to have his discussion with Varys, as seeing the Spider unveil the sorcerer who ?cut? him was as much a testament to the virtue of patience as it was to the power of retribution.
Meanwhile, Jaime and Brienne continue to be the most interesting odd couple in Westeros, as their situation has forced a fascinating shift not only in the dynamic between the two, but also a severe and remarkable turnaround for a man who previously prided himself on his backstabbing abilities and once shoved a child from a tower window after an improper dalliance with his sister.
Now the Kingslayer is but a shell of his former self, a one-handed swordsman who has spent the last year in a cage and in chains; in his mind, the list of reasons to carry on is probably pretty short. But, for his sake, Brienne is there to talk up the intrinsic worth of living life for the sole purpose of enacting revenge on those who wronged you. ?One misfortune and you?re giving up?? she asks, which is both her idea of a pep talk and an illustration of how unpleasant this world is when having your hand hacked off by a rapist with a bad goatee is considered but a ?misfortune.?
![[ Back to EurekAlert! ]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_s6cXqQjSU3Q-k5ncSkzJJd5_GZEk5Ni63gO_hOL8xURw7Tl3ulSsiOVTKyxezHPQhwcrTPf4fu-1FduKLn4-7xJNJ66LiDNOEHhJvkdRI=s0-d){kind=small}
Public release date: 1-May-2013
Share ] 
